伊維菌素 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "伊維菌素" in Chinese language version.

refsWebsite

Global rank Chinese rank

51web.archive.org

1^st place

42nih.gov

4^th place

5^th place

33doi.org

2^nd place

23^rd place

4europa.eu

68^th place

209^th place

4drugs.com

399^th place

208^th place

4google.co.jp

934^th place

984^th place

4who.int

195^th place

179^th place

4fda.gov

447^th place

581^st place

3books.google.com

3^rd place

8^th place

3semanticscholar.org

11^th place

332^nd place

3worldcat.org

5^th place

12^th place

2merck.com

6,464^th place

3,752^nd place

2handle.net

102^nd place

492^nd place

2ghostarchive.org

32^nd place

657^th place

2pebmed.com.br

low place

2harvard.edu

18^th place

57^th place

2cdc.gov

218^th place

198^th place

1hres.ca

low place

1canada.ca

1,712^th place

3,316^th place

1bi-animalhealth.com

low place

1clincalc.com

3,912^th place

5,917^th place

1theguardian.com

12^th place

60^th place

1politifact.com

3,208^th place

7,644^th place

1archive.org

6^th place

4^th place

1acs.org

1,248^th place

434^th place

1nobelprize.org

301^st place

262^nd place

1inchem.org

4,334^th place

2,287^th place

1pdr.net

low place

1aap.org

low place

5,304^th place

1aafp.org

1,916^th place

1,764^th place

1jamanetwork.com

2,650^th place

1,976^th place

1uto.edu.bo

low place

1bbc.co.uk

8^th place

32^nd place

1oup.com

485^th place

489^th place

1sciencebasedmedicine.org

5,063^rd place

low place

1infectologia.org.br

low place

1alivepharmaceutical.blogspot.com

low place

aafp.org

Fawcett RS. Ivermectin Use in Scabies. American Family Physician. 2003-09-15, 68 (6): 1089–1092 [2022 -04-02]. ISSN 0002-838X. PMID 14524395. （原始内容存档于2021-12-27）.

aap.org

publications.aap.org

Ivermectin – Drug Monographs – Pediatric Care Online. American Academy of Pediatrics Drug Monographs. August 2021 [2022-04-02]. （原始内容存档于2022-06-10）.

acs.org

pubs.acs.org

W. C. CAMPBELL; R. W. BURG, , M. H. FISHER, and , R. A. DYBAS. The Discovery of Ivermectin and Other Avermectins. American Chemical Society: 5–20. 1984-06-26 [2015-10-09]. ISBN 9780841210837. （原始内容存档于2019-06-01）. |chapter=被忽略 (帮助)

alivepharmaceutical.blogspot.com

Adhikari S. Alive Pharmaceutical (P) LTD.: Iver-DT. Alive Pharmaceutical (P) LTD. 2014-05-27 [2015-10-07]. （原始内容存档于2016-03-04）.

archive.org

Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.

bbc.co.uk

Schraer, Rachel. Covid: Ivermectin to be studied as possible treatment in UK. BBC News. 2021-06-23 [2021-06-23]. （原始内容存档于2021-07-20）.

bi-animalhealth.com

IVOMEC® (ivermectin). Boehringer Ingelheim Animal Health USA Inc.

books.google.com

Saunders Handbook of Veterinary Drugs: Small and Large Animal 4. Elsevier Health Sciences. 2015: 420. ISBN 978-0-323-24486-2. （原始内容存档于January 31, 2016）.
Omaswa F, Crisp N. African Health Leaders: Making Change and Claiming the Future. OUP Oxford. 2014: PT158 [2020-04-06]. ISBN 978-0191008412. （原始内容存档于2020-08-03）.
Kliegman RM, St Geme J. Nelson Textbook of Pediatrics E-Book. Elsevier Health Sciences. 2019: 3575 [April 6, 2020]. ISBN 978-0323568883. （原始内容存档于2020-08-03）.

canada.ca

Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 2016-05-04 [2024-04-07]. （原始内容存档于2020-02-20）.

cdc.gov

emergency.cdc.gov

Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19 (PDF). CDC Health Alert Network. 2021-08-26,. CDCHAN-00449 [2022-01-04]. （原始内容存档 (PDF)于2021-11-03）.

cdc.gov

Scabies – Medications. U.S. Centers for Disease Control and Prevention (CDC). 2019-10-02 [2021-02-11]. （原始内容存档于2015-04-30）.

clincalc.com

Ivermectin Drug Usage Statistics, United States, 2013 - 2022. ClinCalc. [2024-08-30]. （原始内容存档于2020-06-26）.

doi.org

Kern C, Müller P, Chaccour C, Liechti ME, Hammann F, Duthaler U. Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes. Malaria Journal. June 2023, 22 (1): 194. PMC 10290335 . PMID 37355605. doi:10.1186/s12936-023-04624-0 .
Molyneux DH, Ward SA. Reflections on the Nobel Prize for Medicine 2015—The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology. December 2015, 31 (12): 605–607. PMID 26552892. doi:10.1016/j.pt.2015.10.008.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases. February 2021, 103: 214–216. PMC 7709596 . PMID 33278625. doi:10.1016/j.ijid.2020.11.191.
Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. The Cochrane Database of Systematic Reviews. June 2022, 2022 (6): CD015017. PMC 9215332 . PMID 35726131. doi:10.1002/14651858.CD015017.pub3.
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. April 2021, 27 (3): 156–158. PMID 33888547. doi:10.1136/bmjebm-2021-111678 .
Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.
Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. The Journal of Antibiotics. May 2017, 70 (5): 495–505. PMID 28196978. doi:10.1038/ja.2017.11 .
Ashour DS. Ivermectin: From theory to clinical application. International Journal of Antimicrobial Agents. August 2019, 54 (2): 134–142. PMID 31071469. S2CID 149445017. doi:10.1016/j.ijantimicag.2019.05.003.
Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno J, Gardon J, Boussinesq M, Muñoz J, Krolewiecki A. Safety of high-dose ivermectin: a systematic review and meta-analysis. The Journal of Antimicrobial Chemotherapy. April 2020, 75 (4): 827–834. PMID 31960060. doi:10.1093/jac/dkz524.
Martin RJ, Robertson AP, Choudhary S. Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends in Parasitology. January 2021, 37 (1): 48–64. PMC 7853155 . PMID 33189582. doi:10.1016/j.pt.2020.10.005 .
Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, Ranque S, Ernould JC, Garcia A, Boussinesq M. Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis. Open Forum Infectious Diseases. April 2019, 6 (4): ofz019. PMC 6449757 . PMID 30968052. doi:10.1093/ofid/ofz019.
Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLOS Neglected Tropical Diseases. April 2021, 15 (4): e0009354. PMC 8087035 . PMID 33878105. doi:10.1371/journal.pntd.0009354 . Few hours after administration: nausea, vomiting, abdominal pain, salivation, tachycardia, hypotension, ataxia, pyramidal signs, binocular diplopia
El-Saber Batiha G, Alqahtani A, Ilesanmi OB, Saati AA, El-Mleeh A, Hetta HF, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals //www.ncbi.nlm.nih.gov/pmc/articles/PMC7464486 |PMC=缺少标题 (帮助). August 2020, 13 (8): 196. PMC 7464486 . PMID 32824399. doi:10.3390/ph13080196 . Based on the reported neurotoxicity and metabolic pathway of IVM, caution should be taken to conduct clinical trial on its antiviral potentials. The GABA-gated chloride channels in the human nervous system might be a target for IVM, this is because the BBB in disease-patient might be weakened as a result of inflammation and other destructive processes, allowing IVM to cross the BBB and gain access to the CNS where it can elicit its neurotoxic effect
Omura S, Crump A. Ivermectin: panacea for resource-poor communities?. Trends in Parasitology. September 2014, 30 (9): 445–455. PMID 25130507. doi:10.1016/j.pt.2014.07.005 .
Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. International Journal of Dermatology. December 2005, 44 (12): 981–988. PMID 16409259. doi:10.1111/j.1365-4632.2004.02253.x.
Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg?. Archives of Disease in Childhood. May 2018, 103 (5): 514–519. PMID 29463522. S2CID 3441595. doi:10.1136/archdischild-2017-314505.
Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: Review of dermatologic drugs. International Journal of Women's Dermatology. September 2019, 5 (4): 216–226. PMC 6831768 . PMID 31700976. doi:10.1016/j.ijwd.2019.05.002.
Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. The Lancet. Global Health //www.ncbi.nlm.nih.gov/pmc/articles/PMC7613514 |PMC=缺少标题 (帮助). January 2020, 8 (1): e92–e100. PMC 7613514 . PMID 31839144. doi:10.1016/S2214-109X(19)30453-X .
Campbell WC. Serendipity and new drugs for infectious disease. ILAR Journal. 2005-01-01, 46 (4): 352–356. PMID 16179743. doi:10.1093/ilar.46.4.352 .
Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends in Parasitology. November 2005, 21 (11): 530–532. PMID 16126457. doi:10.1016/j.pt.2005.08.014.
Laing R, Gillan V, Devaney E. Ivermectin – Old Drug, New Tricks?. Trends in Parasitology. June 2017, 33 (6): 463–472. PMC 5446326 . PMID 28285851. doi:10.1016/j.pt.2017.02.004.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. September 2020, 73 (9): 593–602. PMC 7290143 . PMID 32533071. doi:10.1038/s41429-020-0336-z.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. April 2020, 178: 104787. PMC 7129059 . PMID 32251768. doi:10.1016/j.antiviral.2020.104787.
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. April 2020, 50 (SI-1): 611–619. PMC 7195979 . PMID 32293834. doi:10.3906/sag-2004-145 .
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Research. June 2020, 178: 104805. PMC 7172803 . PMID 32330482. doi:10.1016/j.antiviral.2020.104805.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）.
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ (Systematic review). April 2021, 373: n949. PMC 8073806 . PMID 33903131. doi:10.1136/bmj.n949.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2021-06-28 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .
Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 2011, 87 (2): 13–28. Bibcode:2011PJAB...87...13C. PMC 3043740 . PMID 21321478. doi:10.2183/pjab.87.13.
Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, Varela B, Hill M, Verdes JM, Duhalde Vega M, Bollati-Fogolín M, Crispo M. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scientific Reports. March 2021, 11 (1): 7132. Bibcode:2021NatSR..11.7132A. PMC 8010049 . PMID 33785846. doi:10.1038/s41598-021-86679-0.
Pampiglione S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1985, 79 (6): 797–799. PMID 3832491. doi:10.1016/0035-9203(85)90121-X.

drugs.com

Ivermectin. The American Society of Health-System Pharmacists. [Jan 2016]. （原始内容存档于2016-01-03）.
Ivermectin Levels and Effects while Breastfeeding. [2016-01-16]. （原始内容存档于2016-01-01）.
Ivermectin (topical). The American Society of Health-System Pharmacists. 2020-07-27 [2021-01-16]. （原始内容存档于2023-03-18）.
Ivermectin Levels and Effects while Breastfeeding. Drugs.com. [2016-01-16]. （原始内容存档于2016-01-01）.

europa.eu

ema.europa.eu

List of nationally authorised medicinal products (PDF). European Medicines Agency. 2020-11-26. （原始内容存档 (PDF)于2020-12-28）.
Ivermectin/Albendazole - opinion on medicine for use outside EU. European Medicines Agency (EMA). 2025-01-30 [2025-02-16]. （原始内容存档于2025-04-03）.
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. European Medicines Agency. 2021-03-22 [2022 -12-15]. （原始内容存档于2022-01-17）.
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials (新闻稿). European Medicines Agency. 22 March 2021 [2021-07-11]. （原始内容存档于2021-08-04）.

fda.gov

accessdata.fda.gov

Ivermectin: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2021-09-26]. （原始内容存档于2021-11-28）.
Ivermectin lotion: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2021-09-25]. （原始内容存档于2021-09-26）.

fda.gov

Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 2021-12-10 [2021-07-13]. （原始内容存档于2021-08-06）.
Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 5 March 2021 [5 March 2021]. （原始内容存档于2021-08-06）.

ghostarchive.org

Strongyloidiasis. World Health Organization. [2021-01-25]. （原始内容存档于2021-10-19）.
Young C, Argáez C. Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019 [2020-07-04]. PMID 31487135. （原始内容存档于2021-10-19）.

google.co.jp

books.google.co.jp

Sneader, Walter. Drug Discovery a History.. Chichester: John Wiley & Sons. 2005: 333 [2016-01-24]. ISBN 9780470015520. （原始内容存档于2016-01-31）.
Hamilton, Richard J. Tarascon pocket pharmacopoeia : 2014 deluxe lab-pocket edition 15th edition. Sudbury: Jones & Bartlett Learning. 2014: 422 [2016-01-24]. ISBN 9781284053999. （原始内容存档于2016-01-31）.
Mehlhorn, Heinz. Encyclopedia of parasitology 3rd ed. Berlin: Springer. 2008: 646 [2016-01-24]. ISBN 9783540489948. （原始内容存档于2016-01-31）.
Vercruysse, edited by J.; Rew, R.S. Macrocyclic lactones in antiparasitic therapy. Oxon, UK: CABI Pub. 2002: Preface [2016-01-24]. ISBN 9780851998404. （原始内容存档于2016-01-31）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.

harvard.edu

ui.adsabs.harvard.edu

Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 2011, 87 (2): 13–28. Bibcode:2011PJAB...87...13C. PMC 3043740 . PMID 21321478. doi:10.2183/pjab.87.13.
Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, Varela B, Hill M, Verdes JM, Duhalde Vega M, Bollati-Fogolín M, Crispo M. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scientific Reports. March 2021, 11 (1): 7132. Bibcode:2021NatSR..11.7132A. PMC 8010049 . PMID 33785846. doi:10.1038/s41598-021-86679-0.

hres.ca

hpr-rps.hres.ca

Regulatory Decision Summary for Stromectol. 2014-10-23 [2022-06-07]. （原始内容存档于2022-06-07）.

inchem.org

Ivermectin (PIM 292). inchem.org. InChem. [2022-04-03]. （原始内容存档于2022-04-26）.

infectologia.org.br

Atualizações e Recomendações sobre a Covid-19 [Updates and recommendations on Covid-19] (PDF). Sociedade Brasileira de Infectologia. 2020-12-09 [2021-07-11]. （原始内容存档 (PDF)于2021-03-22）（葡萄牙语）.

jamanetwork.com

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）.

merck.com

STROMECTOL® (IVERMECTIN) TABLETS. Merck & Co., Inc.
Merck Statement on Ivermectin use During the COVID-19 Pandemic. Merck. 2021-02-04 [2021-07-11]. （原始内容存档于2021-08-03）.

nih.gov

ncbi.nlm.nih.gov

Kern C, Müller P, Chaccour C, Liechti ME, Hammann F, Duthaler U. Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes. Malaria Journal. June 2023, 22 (1): 194. PMC 10290335 . PMID 37355605. doi:10.1186/s12936-023-04624-0 .
Panahi, Y; Poursaleh, Z; Goldust, M. The efficacy of topical and oral ivermectin in the treatment of human scabies.. Annals of parasitology. 2015, 61 (1): 11–6. PMID 25911032.
Molyneux DH, Ward SA. Reflections on the Nobel Prize for Medicine 2015—The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology. December 2015, 31 (12): 605–607. PMID 26552892. doi:10.1016/j.pt.2015.10.008.
Ahmed S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M, Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases. February 2021, 103: 214–216. PMC 7709596 . PMID 33278625. doi:10.1016/j.ijid.2020.11.191.
Popp M, Reis S, Schießer S, Hausinger RI, Stegemann M, Metzendorf MI, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. The Cochrane Database of Systematic Reviews. June 2022, 2022 (6): CD015017. PMC 9215332 . PMID 35726131. doi:10.1002/14651858.CD015017.pub3.
Garegnani LI, Madrid E, Meza N. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19. BMJ Evidence-Based Medicine. April 2021, 27 (3): 156–158. PMID 33888547. doi:10.1136/bmjebm-2021-111678 .
Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. Annu. Rev. Pharmacol. Toxicol. 1992, 32: 537–53. PMID 1605577. doi:10.1146/annurev.pa.32.040192.002541.
Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. The Journal of Antibiotics. May 2017, 70 (5): 495–505. PMID 28196978. doi:10.1038/ja.2017.11 .
Ashour DS. Ivermectin: From theory to clinical application. International Journal of Antimicrobial Agents. August 2019, 54 (2): 134–142. PMID 31071469. S2CID 149445017. doi:10.1016/j.ijantimicag.2019.05.003.
Navarro M, Camprubí D, Requena-Méndez A, Buonfrate D, Giorli G, Kamgno J, Gardon J, Boussinesq M, Muñoz J, Krolewiecki A. Safety of high-dose ivermectin: a systematic review and meta-analysis. The Journal of Antimicrobial Chemotherapy. April 2020, 75 (4): 827–834. PMID 31960060. doi:10.1093/jac/dkz524.
Martin RJ, Robertson AP, Choudhary S. Ivermectin: An Anthelmintic, an Insecticide, and Much More. Trends in Parasitology. January 2021, 37 (1): 48–64. PMC 7853155 . PMID 33189582. doi:10.1016/j.pt.2020.10.005 .
Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, Ranque S, Ernould JC, Garcia A, Boussinesq M. Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis. Open Forum Infectious Diseases. April 2019, 6 (4): ofz019. PMC 6449757 . PMID 30968052. doi:10.1093/ofid/ofz019.
Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLOS Neglected Tropical Diseases. April 2021, 15 (4): e0009354. PMC 8087035 . PMID 33878105. doi:10.1371/journal.pntd.0009354 . Few hours after administration: nausea, vomiting, abdominal pain, salivation, tachycardia, hypotension, ataxia, pyramidal signs, binocular diplopia
El-Saber Batiha G, Alqahtani A, Ilesanmi OB, Saati AA, El-Mleeh A, Hetta HF, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals //www.ncbi.nlm.nih.gov/pmc/articles/PMC7464486 |PMC=缺少标题 (帮助). August 2020, 13 (8): 196. PMC 7464486 . PMID 32824399. doi:10.3390/ph13080196 . Based on the reported neurotoxicity and metabolic pathway of IVM, caution should be taken to conduct clinical trial on its antiviral potentials. The GABA-gated chloride channels in the human nervous system might be a target for IVM, this is because the BBB in disease-patient might be weakened as a result of inflammation and other destructive processes, allowing IVM to cross the BBB and gain access to the CNS where it can elicit its neurotoxic effect
Omura S, Crump A. Ivermectin: panacea for resource-poor communities?. Trends in Parasitology. September 2014, 30 (9): 445–455. PMID 25130507. doi:10.1016/j.pt.2014.07.005 .
Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. International Journal of Dermatology. December 2005, 44 (12): 981–988. PMID 16409259. doi:10.1111/j.1365-4632.2004.02253.x.
Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg?. Archives of Disease in Childhood. May 2018, 103 (5): 514–519. PMID 29463522. S2CID 3441595. doi:10.1136/archdischild-2017-314505.
Fawcett RS. Ivermectin Use in Scabies. American Family Physician. 2003-09-15, 68 (6): 1089–1092 [2022 -04-02]. ISSN 0002-838X. PMID 14524395. （原始内容存档于2021-12-27）.
Koh YP, Tian EA, Oon HH. New changes in pregnancy and lactation labelling: Review of dermatologic drugs. International Journal of Women's Dermatology. September 2019, 5 (4): 216–226. PMC 6831768 . PMID 31700976. doi:10.1016/j.ijwd.2019.05.002.
Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Menéndez C, Bardají A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. The Lancet. Global Health //www.ncbi.nlm.nih.gov/pmc/articles/PMC7613514 |PMC=缺少标题 (帮助). January 2020, 8 (1): e92–e100. PMC 7613514 . PMID 31839144. doi:10.1016/S2214-109X(19)30453-X .
Campbell WC. Serendipity and new drugs for infectious disease. ILAR Journal. 2005-01-01, 46 (4): 352–356. PMID 16179743. doi:10.1093/ilar.46.4.352 .
Geary TG. Ivermectin 20 years on: maturation of a wonder drug. Trends in Parasitology. November 2005, 21 (11): 530–532. PMID 16126457. doi:10.1016/j.pt.2005.08.014.
Laing R, Gillan V, Devaney E. Ivermectin – Old Drug, New Tricks?. Trends in Parasitology. June 2017, 33 (6): 463–472. PMC 5446326 . PMID 28285851. doi:10.1016/j.pt.2017.02.004.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics. September 2020, 73 (9): 593–602. PMC 7290143 . PMID 32533071. doi:10.1038/s41429-020-0336-z.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research. April 2020, 178: 104787. PMC 7129059 . PMID 32251768. doi:10.1016/j.antiviral.2020.104787.
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences. April 2020, 50 (SI-1): 611–619. PMC 7195979 . PMID 32293834. doi:10.3906/sag-2004-145 .
Bray M, Rayner C, Noël F, Jans D, Wagstaff K. Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral Research. June 2020, 178: 104805. PMC 7172803 . PMID 32330482. doi:10.1016/j.antiviral.2020.104805.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）.
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Bartoszko JJ, Siemieniuk RA, Kum E, Qasim A, Zeraatkar D, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ (Systematic review). April 2021, 373: n949. PMC 8073806 . PMID 33903131. doi:10.1136/bmj.n949.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2021-06-28 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .
Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences. 2011, 87 (2): 13–28. Bibcode:2011PJAB...87...13C. PMC 3043740 . PMID 21321478. doi:10.2183/pjab.87.13.
Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, Varela B, Hill M, Verdes JM, Duhalde Vega M, Bollati-Fogolín M, Crispo M. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scientific Reports. March 2021, 11 (1): 7132. Bibcode:2021NatSR..11.7132A. PMC 8010049 . PMID 33785846. doi:10.1038/s41598-021-86679-0.
Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019 [2020-07-04]. PMID 31424718. （原始内容存档于2023-03-18）.
Young C, Argáez C. Ivermectin for Parasitic Skin Infections of Lice: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019 [2020-07-04]. PMID 31487135. （原始内容存档于2021-10-19）.
Pampiglione S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1985, 79 (6): 797–799. PMID 3832491. doi:10.1016/0035-9203(85)90121-X.

dailymed.nlm.nih.gov

Stromectol – ivermectin tablet. DailyMed. December 15, 2019 [2020-10-28]. （原始内容存档于2020-10-31）.
Soolantra – ivermectin cream. DailyMed. [2021-07-18]. （原始内容存档于2021-07-19）.
Sklice – ivermectin lotion. DailyMed. 2017-11-09 [2020-10-28]. （原始内容存档于2020-10-31）.

nih.gov

COVID-19 Therapeutics Prioritized for Testing in Clinical Trials. National Institutes of Health. [2021-06-27]. （原始内容存档于2021-08-05）.

covid19treatmentguidelines.nih.gov

The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19. National Institutes of Health. 2020-01-14 [2021-07-11]. （原始内容存档于2021-02-08）.

nobelprize.org

The Nobel Prize in Physiology or Medicine 2015. Nobel Foundation. [2020-05-06]. （原始内容存档于2021-02-09）.

oup.com

academic.oup.com

Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2021-06-28 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.

pdr.net

Stromectol (ivermectin) dose, indications, adverse effects, interactions. www.pdr.net. Prescribers' Digital Reference. [2022-04-03]. （原始内容存档于2022-04-25）.

pebmed.com.br

Quintanilha, Dayana de Oliveira. Anvisa se manifesta contra o uso da ivermectina na Covid-19 [Anvisa speaks out against the use of ivermectin in Covid-19]. PEBMED. 2020-07-13 [2021-07-11]. （原始内容存档于2021-07-12）（葡萄牙语）.
Posicionamento da Sociedade Brasileira de Pneumologia e Tisiologia Sobre o Colapso em Manaus e Tratamento Preventivo e Precoce da Covid-19 [Brazilian Thoracic Society Position Statement on the Collapse in Manaus and the Preventive and Early Treatment of Covid-19]. Sociedade Brasileira de Pneumologia e Tisiologia. 2021-01-17 [2021-01-18]. （原始内容存档于2021-07-12）（葡萄牙语）.

politifact.com

Fact-checking claim about the use of ivermectin to treat COVID-19. PolitiFact (Washington, DC). 2021-04-23 [2021-05-26]. （原始内容存档于2023-03-18）.

sciencebasedmedicine.org

Gorski DH. Ivermectin is the new hydroxychloroquine. Science-Based Medicine. 15 April 2021 [2021-07-11]. （原始内容存档于2021-07-12）.

semanticscholar.org

api.semanticscholar.org

Ashour DS. Ivermectin: From theory to clinical application. International Journal of Antimicrobial Agents. August 2019, 54 (2): 134–142. PMID 31071469. S2CID 149445017. doi:10.1016/j.ijantimicag.2019.05.003.
Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg?. Archives of Disease in Childhood. May 2018, 103 (5): 514–519. PMID 29463522. S2CID 3441595. doi:10.1136/archdischild-2017-314505.
Wadvalla BA. Covid-19: Ivermectin's politicisation is a warning sign for doctors turning to orphan treatments. BMJ. April 2021, 373: n747. PMID 33795225. S2CID 232484313. doi:10.1136/bmj.n747 .

theguardian.com

Evershed N, McGowan M, Ball A. Anatomy of a conspiracy theory: how misinformation travels on Facebook. The Guardian. 2021-03-10 [2021-05-26]. （原始内容存档于2023-03-18）.

uto.edu.bo

dicyt.uto.edu.bo

Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.

web.archive.org

Regulatory Decision Summary for Stromectol. 2014-10-23 [2022-06-07]. （原始内容存档于2022-06-07）.
Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 2016-05-04 [2024-04-07]. （原始内容存档于2020-02-20）.
Stromectol – ivermectin tablet. DailyMed. December 15, 2019 [2020-10-28]. （原始内容存档于2020-10-31）.
Soolantra – ivermectin cream. DailyMed. [2021-07-18]. （原始内容存档于2021-07-19）.
List of nationally authorised medicinal products (PDF). European Medicines Agency. 2020-11-26. （原始内容存档 (PDF)于2020-12-28）.
Saunders Handbook of Veterinary Drugs: Small and Large Animal 4. Elsevier Health Sciences. 2015: 420. ISBN 978-0-323-24486-2. （原始内容存档于January 31, 2016）.
Ivermectin. The American Society of Health-System Pharmacists. [Jan 2016]. （原始内容存档于2016-01-03）.
Sneader, Walter. Drug Discovery a History.. Chichester: John Wiley & Sons. 2005: 333 [2016-01-24]. ISBN 9780470015520. （原始内容存档于2016-01-31）.
Hamilton, Richard J. Tarascon pocket pharmacopoeia : 2014 deluxe lab-pocket edition 15th edition. Sudbury: Jones & Bartlett Learning. 2014: 422 [2016-01-24]. ISBN 9781284053999. （原始内容存档于2016-01-31）.
Mehlhorn, Heinz. Encyclopedia of parasitology 3rd ed. Berlin: Springer. 2008: 646 [2016-01-24]. ISBN 9783540489948. （原始内容存档于2016-01-31）.
Ivermectin Levels and Effects while Breastfeeding. [2016-01-16]. （原始内容存档于2016-01-01）.
Vercruysse, edited by J.; Rew, R.S. Macrocyclic lactones in antiparasitic therapy. Oxon, UK: CABI Pub. 2002: Preface [2016-01-24]. ISBN 9780851998404. （原始内容存档于2016-01-31）.
Ivermectin Drug Usage Statistics, United States, 2013 - 2022. ClinCalc. [2024-08-30]. （原始内容存档于2020-06-26）.
Ivermectin: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2021-09-26]. （原始内容存档于2021-11-28）.
Ivermectin lotion: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2021-09-25]. （原始内容存档于2021-09-26）.
Ivermectin/Albendazole - opinion on medicine for use outside EU. European Medicines Agency (EMA). 2025-01-30 [2025-02-16]. （原始内容存档于2025-04-03）.
Evershed N, McGowan M, Ball A. Anatomy of a conspiracy theory: how misinformation travels on Facebook. The Guardian. 2021-03-10 [2021-05-26]. （原始内容存档于2023-03-18）.
Fact-checking claim about the use of ivermectin to treat COVID-19. PolitiFact (Washington, DC). 2021-04-23 [2021-05-26]. （原始内容存档于2023-03-18）.
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials. European Medicines Agency. 2021-03-22 [2022 -12-15]. （原始内容存档于2022-01-17）.
Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 2021-12-10 [2021-07-13]. （原始内容存档于2021-08-06）.
Rapid Increase in Ivermectin Prescriptions and Reports of Severe Illness Associated with Use of Products Containing Ivermectin to Prevent or Treat COVID-19 (PDF). CDC Health Alert Network. 2021-08-26,. CDCHAN-00449 [2022-01-04]. （原始内容存档 (PDF)于2021-11-03）.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organization (WHO). [2022-01-04]. （原始内容存档于2021-08-05）.
W. C. CAMPBELL; R. W. BURG, , M. H. FISHER, and , R. A. DYBAS. The Discovery of Ivermectin and Other Avermectins. American Chemical Society: 5–20. 1984-06-26 [2015-10-09]. ISBN 9780841210837. （原始内容存档于2019-06-01）. |chapter=被忽略 (帮助)
The Nobel Prize in Physiology or Medicine 2015. Nobel Foundation. [2020-05-06]. （原始内容存档于2021-02-09）.
Onchocerciasis. World Health Organization. 2019-06-14 [2021-01-11]. （原始内容存档于2020-04-11）.
Scabies – Medications. U.S. Centers for Disease Control and Prevention (CDC). 2019-10-02 [2021-02-11]. （原始内容存档于2015-04-30）.
Ivermectin (topical). The American Society of Health-System Pharmacists. 2020-07-27 [2021-01-16]. （原始内容存档于2023-03-18）.
Ivermectin Levels and Effects while Breastfeeding. Drugs.com. [2016-01-16]. （原始内容存档于2016-01-01）.
Ivermectin (PIM 292). inchem.org. InChem. [2022-04-03]. （原始内容存档于2022-04-26）.
Stromectol (ivermectin) dose, indications, adverse effects, interactions. www.pdr.net. Prescribers' Digital Reference. [2022-04-03]. （原始内容存档于2022-04-25）.
Ivermectin – Drug Monographs – Pediatric Care Online. American Academy of Pediatrics Drug Monographs. August 2021 [2022-04-02]. （原始内容存档于2022-06-10）.
Fawcett RS. Ivermectin Use in Scabies. American Family Physician. 2003-09-15, 68 (6): 1089–1092 [2022 -04-02]. ISSN 0002-838X. PMID 14524395. （原始内容存档于2021-12-27）.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）.
Yang SN, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer (PDF). Antiviral Research. May 2020, 177: 104760 [2021-07-11]. PMID 32135219. doi:10.1016/j.antiviral.2020.104760. （原始内容存档 (PDF)于2020-07-13）.
Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration (FDA). 5 March 2021 [5 March 2021]. （原始内容存档于2021-08-06）.
Schraer, Rachel. Covid: Ivermectin to be studied as possible treatment in UK. BBC News. 2021-06-23 [2021-06-23]. （原始内容存档于2021-07-20）.
COVID-19 Therapeutics Prioritized for Testing in Clinical Trials. National Institutes of Health. [2021-06-27]. （原始内容存档于2021-08-05）.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2021-06-28 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.
Gorski DH. Ivermectin is the new hydroxychloroquine. Science-Based Medicine. 15 April 2021 [2021-07-11]. （原始内容存档于2021-07-12）.
Merck Statement on Ivermectin use During the COVID-19 Pandemic. Merck. 2021-02-04 [2021-07-11]. （原始内容存档于2021-08-03）.
The COVID-19 Treatment Guidelines Panel's Statement on the Use of Ivermectin for the Treatment of COVID-19. National Institutes of Health. 2020-01-14 [2021-07-11]. （原始内容存档于2021-02-08）.
EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials (新闻稿). European Medicines Agency. 22 March 2021 [2021-07-11]. （原始内容存档于2021-08-04）.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organisation. 2021-03-31 [2021-07-11]. （原始内容存档于2021-08-05）.
Quintanilha, Dayana de Oliveira. Anvisa se manifesta contra o uso da ivermectina na Covid-19 [Anvisa speaks out against the use of ivermectin in Covid-19]. PEBMED. 2020-07-13 [2021-07-11]. （原始内容存档于2021-07-12）（葡萄牙语）.
Atualizações e Recomendações sobre a Covid-19 [Updates and recommendations on Covid-19] (PDF). Sociedade Brasileira de Infectologia. 2020-12-09 [2021-07-11]. （原始内容存档 (PDF)于2021-03-22）（葡萄牙语）.
Posicionamento da Sociedade Brasileira de Pneumologia e Tisiologia Sobre o Colapso em Manaus e Tratamento Preventivo e Precoce da Covid-19 [Brazilian Thoracic Society Position Statement on the Collapse in Manaus and the Preventive and Early Treatment of Covid-19]. Sociedade Brasileira de Pneumologia e Tisiologia. 2021-01-17 [2021-01-18]. （原始内容存档于2021-07-12）（葡萄牙语）.
Omaswa F, Crisp N. African Health Leaders: Making Change and Claiming the Future. OUP Oxford. 2014: PT158 [2020-04-06]. ISBN 978-0191008412. （原始内容存档于2020-08-03）.
Kliegman RM, St Geme J. Nelson Textbook of Pediatrics E-Book. Elsevier Health Sciences. 2019: 3575 [April 6, 2020]. ISBN 978-0323568883. （原始内容存档于2020-08-03）.
Chiu S, Argaez C. Ivermectin for Parasitic Skin Infections of Scabies: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines. CADTH Rapid Response Reports. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019 [2020-07-04]. PMID 31424718. （原始内容存档于2023-03-18）.
Sklice – ivermectin lotion. DailyMed. 2017-11-09 [2020-10-28]. （原始内容存档于2020-10-31）.
Adhikari S. Alive Pharmaceutical (P) LTD.: Iver-DT. Alive Pharmaceutical (P) LTD. 2014-05-27 [2015-10-07]. （原始内容存档于2016-03-04）.

who.int

WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organization (WHO). [2022-01-04]. （原始内容存档于2021-08-05）.
Onchocerciasis. World Health Organization. 2019-06-14 [2021-01-11]. （原始内容存档于2020-04-11）.
Strongyloidiasis. World Health Organization. [2021-01-25]. （原始内容存档于2021-10-19）.
WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. World Health Organisation. 2021-03-31 [2021-07-11]. （原始内容存档于2021-08-05）.

worldcat.org

Fawcett RS. Ivermectin Use in Scabies. American Family Physician. 2003-09-15, 68 (6): 1089–1092 [2022 -04-02]. ISSN 0002-838X. PMID 14524395. （原始内容存档于2021-12-27）.
López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA. 2021-03-04, 325 (14): 1426–1435 [2021-07-11]. ISSN 0098-7484. PMC 7934083 . PMID 33662102. doi:10.1001/jama.2021.3071. （原始内容存档于2021-07-31）.
Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. Clinical Infectious Diseases. 2021-06-28 [2021-07-11]. ISSN 1058-4838. PMID 34181716. doi:10.1093/cid/ciab591. （原始内容存档于2021-08-06）.